FUSION PROTEINS FOR HALF-LIFE EXTENSION - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 100

proteins, by creating second-generation proteins with
improved characteristics. This will on one hand enable
life-cycle management for some companies with established
drugs, but on the other hand enable new market entrants to
place novel variants of a proven product.

15. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral
OK, Chen C, et al. (2005) Development of a long-acting insulin
analog using albumin fusion technology. Diabetes 54(1),
251-258.
16. Weimer T, Wormsbacher W, Kronthaler U, Lang W, Liebing U,
Schulte S. (2008) Prolonged in-vivo half-life of factor VIIa by
fusion to albumin. Thromb. Haemost. 99(4), 659-667.
17. Schulte S. (2009) Half-life extension through albumin fusion
technologies. Thromb. Res. 124(Suppl 2), S6-8.
18. Zhao HL, Xue C, Du JL, Ren M, Xia S, Liu ZM. (2012)
Balancing the pharmacokinetics and pharmacodynamics of
interferon- a 2b and human serum albumin fusion protein by
proteolytic or reductive cleavage increases its in vivo thera-
peutic efficacy. Mol. Pharm. 9(3), 664-670.
19. Zhan J, Chen Y, Yuan H-Y, Li H, Lu H. (2012) Fusion of HSA
influences TNF- a neutralizing activity of shTNFRs. Biotech-
nol. Lett. 34(3), 417-423.
20. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-
Stec EM, Hartnett C, et al. (2003) Cytokine traps: multi-
component, high-affinity blockers of cytokine action. Nat.
Med. 9(1), 47-52.
21. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-
Toyoda T, Kawanishi T, et al. (2010) Importance of neonatal
FcR in regulating the serum half-life of therapeutic proteins
containing the Fc domain of human IgG1: a comparative study
of the affinity of monoclonal antibodies and Fc-fusion proteins
to human neonatal FcR. J. Immunol. 184(4), 1968-1976.
22. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung
IWL, Sproule TJ, et al. (2010) Enhanced antibody half-life
improves in vivo activity. Nat. Biotechnol. 28(2), 157-159.
23. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE,
Palombella VJ, et al. (2004) Pulmonary delivery of an eryth-
ropoietin Fc fusion protein in non-human primates through
an immunoglobulin transport pathway. Proc. Natl. Acad. Sci.
USA 101(26), 9763-9768.
24. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M,
Newman SP. (2005) Delivery of an erythropoietin-Fc fusion
protein by inhalation in humans through an immunoglobulin
transport pathway. J. Aerosol Med. 18(3), 294-303.
25. Vallee S, Rakhe S, Reidy T, Walker S, Lu Q, Sakorafas P, et al.
(2012) Pulmonary administration of interferon Beta-1a-fc
fusion protein in non-human primates using an immuno-
globulin transport pathway. J.

REFERENCES

1. Tryggvason K, Wartiovaara J. (2005) How does the kidney
filter plasma? Physiology (Bethesda) 20, 96-101.
2. Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina
L. (2010) Multivalent antibodies: when design surpasses evo-
lution. Trends Biotechnol. 28(7), 355-362.
3. Beckman RA, Weiner LM, Davis HM. (2007) Antibody con-
structs in cancer therapy: protein engineering strategies to
improve exposure in solid tumors. Cancer 109(2), 170-179.
4. Sarkar CA, Lowenhaupt K, Horan T, Boone TC, Tidor B,
Lauffenburger DA. (2002) Rational cytokine design for
increased lifetime and enhanced potency using pH-activated
“histidine switching”. Nat. Biotechnol. 20(9), 908-913.
5. Woodnutt G, Violand B, North M. (2008) Advances in protein
therapeutics. Curr. Opin. Drug Discov. Deve. 11(6), 754-761.
6. Kontermann RE. (2011) Strategies for extended serum half-
life of protein therapeutics. Curr. Opin. Biotechnol. 22(6),
868-876.
7. Peters TJr., (1985) Serum albumin. Adv. Protein Chem. 37,
161-245.
8. Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A,
Evans L, et al. (2012) Structure-based mutagenesis reveals
the albumin-binding site of the neonatal Fc receptor. Nat.
Commun. 3, 610.
9. Andersen JT, Sandlie I. (2009) The versatile MHC class I-
related FcRn protects IgG and albumin from degradation:
implications for development of new diagnostics and thera-
peutics. Drug Metab. Pharmacokinet. 24(4), 318-332.
10. Wunder A, Stehle G, Sinn H, Schrenk H, Hoffbiederbeck D,
Bader F, et al. (1997) Enhanced albumin uptake by rat tumors.
Int. J. Oncol. 11(3), 497-507.
11. Cordes AA, Carpenter JF, Randolph TW. (2012) Selective
domain stabilization as a strategy to reduce human serum
albumin-human granulocyte colony stimulating factor aggre-
gation rate. J. Pharm. Sci. 101(6), 2009-2016.
12. Evans L, Hughes M, Waters J, Cameron J, Dodsworth N, Tooth
D, et al. (2010) The production, characterisation and enhanced
pharmacokinetics of scFv-albumin fusions expressed in Sac-
charomyces cerevisiae. Protein Expr. Purif. 73(2), 113-124.
13. Zhao HL, Xue C, Wang Y, Li XY, Xiong XH, Yao XQ, et al.
(2007) Circumventing the heterogeneity and instability of
human serum albumin-interferon-alpha2b fusion protein by
altering its orientation. J. Biotechnol. 131(3), 245-252.
14. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S,
McHutchison JG. (2007) Albinterferon alpha-2b: a genetic
fusion protein for the treatment of chronic hepatitis C. Nat.
Biotechnol. 25(12), 1411-1419.

Interferon Cytokine Res.

32(4), 178-184.
26. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006) Monomeric
Fc fusions: impact on pharmacokinetic and biological activity
of protein therapeutics. BioDrugs 20(3), 151-160.
27. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo K-M, et al.
(2010) SEEDbodies: fusion proteins based on strand-
exchange engineered domain (SEED) CH3 heterodimers in
an Fc analogue platform for asymmetric binders or immu-
nofusions and bispecific antibodies. Protein Eng. Des. Sel.
23(4), 195-202.
28. Muda M, Gross AW, Dawson JP, He C, Kurosawa E,
Schweickhardt R, et al. (2011) Therapeutic assessment of
SEED: a new engineered antibody platform designed to